Skip to main content

Table 2 Adverse events of any grade (≥ 15% of patients, safety population)

From: Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide

Treatment-emergent

No

Eltrombopag

Eltrombopag

Eltrombopag

Total

 

Eltrombopag

75 mg

100 mg

150 mg

(N = 15)

 

(n = 3)a

(n = 7)

(n = 4)

(n = 1)

 

Hematologic AEs, n (%)

     

 Thrombocytopenia

2 (67)

5 (71)

4 (100)

1 (100)

12 (80)

 Neutropenia

2 (67)

5 (71)

4 (100)

0

11 (73)

 Anemia

1 (33)

6 (86)

3 (75)

0

10 (67)

 Leukopenia

0

3 (43)

2 (50)

0

5 (33)

 Febrile neutropenia

0

2 (29)

1 (25)

1 (100)

4 (27)

 Thrombocytosis

0

4 (57)

0

0

4 (27)

Nonhematologic AEs, n (%)

     

 Fatigue

0

6 (86)

2 (50)

0

8 (53)

 ALT increased

0

5 (71)

2 (50)

0

7 (47)

 Constipation

0

6 (86)

1 (25)

0

7 (47)

 Nausea

1 (33)

5 (71)

1 (25)

0

7 (47)

 Alopecia

0

5 (71)

1 (25)

0

6 (40)

 Pyrexia

1 (33)

3 (43)

2 (50)

0

6 (40)

 Vomiting

1 (33)

3 (43)

2 (50)

0

6 (40)

 AST increased

0

3 (43)

2 (50)

0

5 (33)

 Hypokalemia

0

3 (43)

2 (50)

0

5 (33)

 Confusional state

1 (33)

2 (29)

0

0

3 (20)

 Hemorrhoids

0

3 (43)

0

0

3 (20)

 Hypocalcemia

0

1 (14)

2 (50)

0

3 (20)

 Headache

0

3 (43)

0

0

3 (20)

 Edema peripheral

1 (33)

1 (14)

1 (25)

0

3 (20)

 Proteinuria

0

3 (43)

0

0

3 (20)

 Vitamin B12 increased

0

3 (43)

0

0

3 (20)

  1. aPatients were withdrawn prior to receiving eltrombopag during the second cycle.
  2. AE, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase.